Product Description
For Influenza (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01740063)
Mechanisms of Action: PIV Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ansun Biopharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| DAS181-2-04 | P2 |
Completed |
Influenza, Human |
2014-01-01 |
2019-07-10 |
Patient Enrollment|Primary Completion Date|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|